JP2005516967A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516967A5
JP2005516967A5 JP2003559508A JP2003559508A JP2005516967A5 JP 2005516967 A5 JP2005516967 A5 JP 2005516967A5 JP 2003559508 A JP2003559508 A JP 2003559508A JP 2003559508 A JP2003559508 A JP 2003559508A JP 2005516967 A5 JP2005516967 A5 JP 2005516967A5
Authority
JP
Japan
Prior art keywords
secretase inhibitor
inhibitor according
manufacture
amyloid
secretase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003559508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/000504 external-priority patent/WO2003059346A1/en
Publication of JP2005516967A publication Critical patent/JP2005516967A/ja
Publication of JP2005516967A5 publication Critical patent/JP2005516967A5/ja
Withdrawn legal-status Critical Current

Links

JP2003559508A 2002-01-18 2003-01-20 β−セクレターゼインヒビター Withdrawn JP2005516967A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02001339 2002-01-18
EP02012566 2002-06-05
PCT/EP2003/000504 WO2003059346A1 (en) 2002-01-18 2003-01-20 Beta-secretase inhibitors

Publications (2)

Publication Number Publication Date
JP2005516967A JP2005516967A (ja) 2005-06-09
JP2005516967A5 true JP2005516967A5 (https=) 2006-01-05

Family

ID=26077568

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559508A Withdrawn JP2005516967A (ja) 2002-01-18 2003-01-20 β−セクレターゼインヒビター

Country Status (6)

Country Link
US (1) US20050239899A1 (https=)
EP (1) EP1467729A1 (https=)
JP (1) JP2005516967A (https=)
AU (1) AU2003205630A1 (https=)
CA (1) CA2473441A1 (https=)
WO (1) WO2003059346A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
WO2005103020A1 (en) 2004-04-20 2005-11-03 Merck & Co., Inc. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006029850A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
EP1802303B1 (en) * 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
PE20070798A1 (es) * 2005-10-31 2007-08-24 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2010005704A (es) * 2007-12-18 2010-08-17 Glenmark Pharmaceuticals Sa Derivados de cromano como modulares del trpv3.
MX2010011762A (es) * 2008-06-17 2011-02-03 Glenmark Pharmaceuticals Sa Derivados de cromano como moduladores del trpv3.
EA019252B1 (ru) 2008-07-23 2014-02-28 Арена Фармасьютикалз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
SI2342205T1 (sl) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
SG10201906876PA (en) 2010-01-27 2019-09-27 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚o-甲基轉移酶活性抑制化合物
TWI653235B (zh) 2013-05-28 2019-03-11 阿斯特捷利康公司 作為抗癌劑之吲哚衍生物
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN109745324B (zh) * 2017-11-06 2026-02-06 中国科学院上海营养与健康研究所 非经典NF-kB通路的小分子抑制剂及其应用
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN112955431A (zh) 2018-09-06 2021-06-11 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309822A (ja) * 1994-05-18 1995-11-28 Asahi Chem Ind Co Ltd フェニルプロピオンアニリド誘導体
TR199900124T2 (xx) * 1996-07-24 1999-03-22 Novartis Ag Ha�ere �ld�r�c� bile�imler
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones

Similar Documents

Publication Publication Date Title
JP2005516967A5 (https=)
ES2613931T3 (es) Compuestos peptídicos para tratar el estado epiléptico refractario
RU2309953C2 (ru) Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
TW200621249A (en) Substituted amide beta secretase inhibitors
JP2006507220A5 (https=)
JP2006512417A5 (https=)
WO2012072713A2 (en) Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
RU2005103398A (ru) Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
JP2007511504A5 (https=)
JP2004505912A5 (https=)
JP2007508360A5 (https=)
JP2006503850A5 (https=)
JP2009515887A5 (https=)
JP2003509349A5 (https=)
JP2006500394A5 (https=)
WO2005056524A3 (en) Therapeutic agents useful for treating pain
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
JP2015535247A5 (https=)
JP2006504738A5 (https=)
JP2004509845A5 (https=)
JP2004534064A5 (https=)
EA200501425A1 (ru) Арилвинилазациклоалкановые соединения и способы их получения и применения
ATE538784T1 (de) Verfahren zur behandlung von substanzbedingten erkrankungen
WO2002036118A3 (en) Heterocyclic derivatives useful as pharmaceutical agents